Phase 3 FORT study of RE-024 in PKAN to begin dosing mid-2017
Protocol development underway for pivotal Phase 3 trial of sparsentan in FSGS
First quarter revenues rose 16 percent to
- End of Phase 2 meeting during the first quarter established regulatory path forward for sparsentan in focal segmental glomerulosclerosis (FSGS); protocol development for single pivotal Phase 3 trial ongoing
- Pivotal FORT study evaluating RE-024 in pantothenate kinase-associated neurodegeneration (PKAN) remains on track to initiate patient dosing mid-year 2017
- Net product sales for the first quarter of 2017 were
$33.6 million , compared to net product sales of$29.0 million for the same period in 2016 - Cash, cash equivalents, marketable securities, and note receivable as of
March 31, 2017 totaled$295.3 million
"I'm very pleased with our progress to start the year," said
Quarter Ended
Net product sales for the first quarter of 2017 were
Research and development (R&D) expenses for the first quarter of 2017 were
Selling, general and administrative (SG&A) expenses for the first quarter of 2017 were
Total other income for the first quarter of 2017 was
Net loss for the first quarter of 2017 was
As of
Program Updates
Sparsentan
- Following an End of Phase 2 meeting with the
U.S. Food and Drug Administration (FDA) during the first quarter of 2017, the Company announced plans to initiate a pivotal Phase 3 clinical trial of sparsentan in FSGS. Notably, the study will include an interim analysis of proteinuria to serve as the basis for an NDA filing for Subpart H accelerated approval of sparsentan. The confirmatory endpoint of the study is expected to compare changes from baseline in estimated glomerular filtration rate, or eGFR, which is widely regarded as the best overall measure of kidney function.
- The Company expects to finalize the Phase 3 protocol and gain alignment with the
FDA in the second half of 2017, with the pivotal trial expected to initiate thereafter.
RE-024
- Recruitment activities for the Phase 3 FORT study of RE-024 have begun, with the first PKAN patient expected to begin dosing mid-year 2017.
- The four PKAN patients receiving RE-024 under physician-initiated treatment outside of the
U.S. continue to receive therapy and remain stable.
Conference Call Information
Retrophin will host a conference call and webcast today,
Use of Non-GAAP Financial Measures
To supplement Retrophin's financial results and guidance presented in accordance with
Investors should note that these non-GAAP financial measures are not prepared under any comprehensive set of accounting rules or principles and do not reflect all of the amounts associated with the Company's results of operations as determined in accordance with GAAP. Investors should also note that these non-GAAP financial measures have no standardized meaning prescribed by GAAP and, therefore, have limits in their usefulness to investors. In addition, from time to time in the future the Company may exclude other items, or cease to exclude items that it has historically excluded, for purposes of its non-GAAP financial measures; because of the non-standardized definitions, the non-GAAP financial measures as used by the Company in this press release and the accompanying tables may be calculated differently from, and therefore may not be directly comparable to, similarly titled measures used by the Company's competitors and other companies.
As used in this press release, (i) the historical non-GAAP net income (loss) measures exclude from GAAP net income (loss), as applicable, revaluation of acquisition related contingent consideration, stock-based compensation expense, depreciation and amortization expense, change in fair value of derivative instruments; income tax benefit; (ii) the historical non-GAAP SG&A expense measures exclude from GAAP SG&A expenses, as applicable, stock-based compensation expense, and depreciation and amortization expense; (iii) the historical non-GAAP R&D expense measures exclude from GAAP R&D expenses, as applicable, stock-based compensation expense, and depreciation and amortization expense.
About Retrophin
Retrophin is a fully integrated biopharmaceutical company dedicated to delivering life-changing therapies to people living with rare diseases who have few, if any, treatment options. The Company's approach centers on its pipeline featuring late-stage assets targeting rare diseases with significant unmet medical needs, including sparsentan for focal segmental glomerulosclerosis (FSGS), a disorder characterized by progressive scarring of the kidney often leading to end-stage renal disease, and RE-024 for pantothenate kinase-associated neurodegeneration (PKAN), a life-threatening neurological disorder that typically begins in early childhood. Research exploring the potential of early-stage assets in several rare diseases is also underway. Retrophin's R&D efforts are supported by revenues from the Company's commercial products Thiola®, Cholbam®, and Chenodal®.
Forward-Looking Statements
This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. Without limiting the foregoing, these statements are often identified by the words "may", "might", "believes", "thinks", "anticipates", "plans", "expects", "intends" or similar expressions. In addition, expressions of our strategies, intentions or plans are also forward-looking statements. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with the Company's business and finances in general, success of its commercial products as well as risks and uncertainties associated with the Company's preclinical and clinical stage pipeline. Specifically, the Company faces risks associated with market acceptance of its marketed products including efficacy, safety, price, reimbursement and benefit over competing therapies. The risks and uncertainties the Company faces with respect to its preclinical and clinical stage pipeline include risk that the Company's clinical candidates will not be found to be safe or effective and that planned clinical trials will not proceed as planned. Specifically, the Company faces the risk that the planned Phase 3 clinical trial of sparsentan will not demonstrate that sparsentan is safe or effective or serve as a basis for accelerated approval of sparsentan as planned; risk that the Phase 3 clinical trial of RE-024 will not demonstrate that RE-024 is safe or effective or serve as the basis for an NDA filing as planned; and risk that the Company's product candidates will not be approved for efficacy, safety, regulatory or other reasons, and for each of the programs, risk associated with enrollment of clinical trials for rare diseases and risk that ongoing or planned clinical trials may not succeed or may be delayed for safety, regulatory or other reasons. The Company faces risk that it will be unable to raise additional funding that may be required to complete development of any or all of its product candidates; risk relating to the Company's dependence on contractors for clinical drug supply and commercial manufacturing; uncertainties relating to patent protection and intellectual property rights of third parties; and risks and uncertainties relating to competitive products and technological changes that may limit demand for the Company's products. You are cautioned not to place undue reliance on these forward-looking statements as there are important factors that could cause actual results to differ materially from those in forward-looking statements, many of which are beyond our control. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Investors are referred to the full discussion of risks and uncertainties as included in the Company's most recent Form 10-K, Form 10-Q and other filings with the
| CONSOLIDATED BALANCE SHEETS | ||||||||
| (in thousands, except share amounts) | ||||||||
| Assets | (unaudited) | |||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 41,871 | $ | 41,002 | ||||
| Marketable securities | 206,290 | 214,871 | ||||||
| Accounts receivable, net | 15,427 | 18,510 | ||||||
| Inventory, net | 4,751 | 2,826 | ||||||
| Prepaid expenses and other current assets | 3,241 | 4,831 | ||||||
| Prepaid taxes | 3,645 | 3,463 | ||||||
| Note receivable, current | 47,173 | 46,849 | ||||||
| Total current assets | 322,398 | 332,352 | ||||||
| Property and equipment, net | 2,428 | 2,587 | ||||||
| Other assets | 3,661 | 7,364 | ||||||
| Intangible assets, net | 180,958 | 182,043 | ||||||
| 936 | 936 | |||||||
| Total assets | $ | 510,381 | $ | 525,282 | ||||
| Liabilities and Stockholders' Equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 4,671 | $ | 7,522 | ||||
| Accrued expenses | 30,192 | 33,308 | ||||||
| Other current liabilities | 1,671 | 1,842 | ||||||
| Guaranteed minimum royalty | 2,000 | 2,000 | ||||||
| Business combination-related contingent consideration | 16,841 | 16,150 | ||||||
| Derivative financial instruments, warrants | 21,180 | 22,440 | ||||||
| Total current liabilities | 76,555 | 83,262 | ||||||
| Convertible debt | 44,583 | 44,422 | ||||||
| Other non-current liabilities | 3,857 | 4,010 | ||||||
| Guaranteed minimum royalty, less current portion | 7,849 | 8,068 | ||||||
| Business combination-related contingent consideration, less current portion | 72,241 | 71,328 | ||||||
| Deferred income tax liability, net | 4,361 | 6,425 | ||||||
| Total liabilities | 209,446 | 217,515 | ||||||
| Stockholders' Equity: | ||||||||
| Preferred stock |
— | — | ||||||
| Common stock |
4 | 4 | ||||||
| Additional paid-in capital | 430,366 | 421,309 | ||||||
| Accumulated deficit | (129,014 | ) | (113,056 | ) | ||||
| Accumulated other comprehensive loss | (421 | ) | (490 | ) | ||||
| Total stockholders' equity | 300,935 | 307,767 | ||||||
| Total liabilities and stockholders' equity | $ | 510,381 | $ | 525,282 | ||||
| CONSOLIDATED STATEMENT OF OPERATIONS | |||||||
| (in thousands, except share and per share data) | |||||||
| (unaudited) | |||||||
| Three Months Ended |
|||||||
| 2017 | 2016 | ||||||
| Net product sales | $ | 33,620 | $ | 29,008 | |||
| Operating expenses: | |||||||
| Cost of goods sold | 709 | 757 | |||||
| Research and development | 20,860 | 14,672 | |||||
| Selling, general and administrative | 23,115 | 19,125 | |||||
| Change in fair value of contingent consideration | 3,344 | 2,695 | |||||
| Total operating expenses | 48,028 | 37,249 | |||||
| Operating loss | (14,408 | ) | (8,241 | ) | |||
| Other income (expenses), net: | |||||||
| Other income, net | 126 | 210 | |||||
| Interest expense, net | (132 | ) | (163 | ) | |||
| Change in fair value of derivative instruments | 1,260 | 14,340 | |||||
| Total other income, net | 1,254 | 14,387 | |||||
| Income (loss) before provision for income taxes | (13,154 | ) | 6,146 | ||||
| Income tax benefit | 2,064 | 5,070 | |||||
| Net income (loss) | $ | (11,090 | ) | $ | 11,216 | ||
| Net earnings (loss) per common share, basic | $ | (0.29 | ) | $ | 0.31 | ||
| Net loss per common share, diluted | $ | (0.32 | ) | $ | (0.08 | ) | |
| Weighted average common shares outstanding, basic | 38,045,317 | 36,520,186 | |||||
| Weighted average common shares outstanding, diluted | 39,158,922 | 37,947,479 | |||||
| RECONCILIATION OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION | ||||||||
| (in thousands, except share and per share data) | ||||||||
| (unaudited) | ||||||||
| Three Months Ended |
||||||||
| 2017 | 2016 | |||||||
| GAAP operating loss | $ | (14,408 | ) | $ | (8,241 | ) | ||
| R&D operating expense | (20,860 | ) | (14,672 | ) | ||||
| Stock compensation | 2,688 | 2,486 | ||||||
| Amortization & depreciation | 81 | 82 | ||||||
| Subtotal non-GAAP items | 2,769 | 2,568 | ||||||
| Non-GAAP R&D expense | (18,091 | ) | (12,104 | ) | ||||
| SG&A operating expense | (23,115 | ) | (19,125 | ) | ||||
| Stock compensation | 4,405 | 4,307 | ||||||
| Amortization & depreciation | 4,203 | 3,810 | ||||||
| Subtotal non-GAAP items | 8,608 | 8,117 | ||||||
| Non-GAAP SG&A expense | (14,507 | ) | (11,008 | ) | ||||
| Change in valuation of contingent consideration | 3,344 | 2,695 | ||||||
| Subtotal non-GAAP items | 14,721 | 13,380 | ||||||
| Non-GAAP operating income | $ | 313 | $ | 5,139 | ||||
| GAAP net income (loss) | $ | (11,090 | ) | $ | 11,216 | |||
| Non-GAAP operating adjustments | 14,721 | 13,380 | ||||||
| Change in fair value of derivative instruments | (1,260 | ) | (14,340 | ) | ||||
| Income tax benefit | (2,064 | ) | (5,070 | ) | ||||
| Non-GAAP net income | $ | 307 | $ | 5,186 | ||||
| Per share data: | ||||||||
| Net earnings per common share, basic | $ | 0.01 | $ | 0.14 | ||||
| Weighted average common shares outstanding, basic | 38,045,317 | 36,520,186 | ||||||
Contact:Chris Cline , CFA Vice President, Investor Relations & Corporate Communications 646-564-3680 IR@retrophin.com
Source:
News Provided by Acquire Media